CALCIUM CHANNEL BLOCKERS: MODERN TOOL TO ACHIEVING TARGET BLOOD PRESSURE


Дәйексөз келтіру

Толық мәтін

Аннотация

The article is dedicated to the role of long-acting calcium channel blockers in the treatment of arterial hypertension (AH) and achievement of target blood pressure. The possibilities of application of the dihydropyridine calcium channel blocker felodipine, including in AH associated with chronic kidney disease are considered. It is emphasized that long-acting dihydropyridine calcium channel blocker can claim to be a universal tool to achieving target blood pressure, including application in difficult clinical situations (isolated systolic arterial hypertension in the elderly, arterial hypertension associated with comorbid conditions and/or target organ damage) .

Авторлар туралы

Viktor Fomin

V Fomin

Әдебиет тізімі

  1. Glynn LG, Murphy AW, Smith SM, et al. Interventions used to improve control of blood pressure in patients with hypertension. Cochrane Database Syst Rev 2010;(3):CD005182.
  2. Комитет экспертов РМОАГ/ВНОК. Диагностика и лечение артериальной гипертензии. (Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов) // Системные гипертензии. 2010. № 3. С. 5-26.
  3. Zoungas S, de Galan BE, Ninomiya T, et al. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial. Diabetes Care 2009;32(11):2068-74.
  4. ACCORD Study Group, Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010;362(17):1575-85.
  5. Waeber B, Mourad JJ, O'Brien E. Nighttime blood pressure: a target for therapy? Curr Hypertens Rep 2010;12(6):474-79.
  6. Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995;92(5):1326-31.
  7. Dahlof B, Sever P, Poulter NR, et al., ASCOT Investigators. Prevention of cardiovascular events with antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendoflumethiazide as required in the Anglo-Scandinavian Cardiac Outcomes Trial - Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005;366:895-906.
  8. Jameson K, Weber MA, Bakris GL, et al., ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359:2417-28.
  9. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997;350:757-64.
  10. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. J. Hypertens 2004;22:847-57.
  11. Forette F, Seux ML, Staessen JA, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998;352:1347-51.
  12. Voyaki S.M, Staessen JA, Thijs L, et al. Follow-up of renal function in treated and untreated older patients with isolated systolic hypertension. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. J Hypertens 2001;19:511-19.
  13. Liu L, Wang JG, Gong L. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group J Hypertens 1998;16(12 Pt 1):1823-9.
  14. Wang JG, Staessen JA, Fagard R. Risks of smoking in treated and untreated older Chinese patients with isolated systolic hypertension. J Hypertens 2001;19:187-92.
  15. Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000;356(9227):366-72.
  16. Mancia G, Brown M, Castaigne A, et al. Outcomes with nifedipine GITS or Co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT). Hypertension 2003;41(3):431-36.
  17. Mancia G, Ruilope L, Palmer C, et al. Effects of nifedipine GITS and diuretics in isolated systolic hypertension - a subanalysis of the INSIGHT study. Blood Press 2004;13(5):310-15.
  18. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351(9118):1755-62.
  19. Kjeldsen SE, Kolloch RE, Leonetti G, et al. Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study. J Hypertens 2000;18(5):629-42.
  20. Liu L, Zhang Y, Liu G, FEVER Study Group. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens 2005;23(12):2157-72.
  21. Zhang Y, Zhang X, Liu L, Zanchetti A, FEVER Study Group. Effects of individual risk factors on the residual risk of cardiovascular events in a population of treated Chinese patients with hypertension: data from the Felodipine Event Reduction (FEVER) study. J Hypertens 2010;28(10):2016-25.
  22. Brun J, Froberg L, Kronmann P, et al. Optimal felodipine dose when combined with metoprolol in arterial hypertension: a Swedish multicenter study within primary health care. Swedish General Practitioner Felodipine Study Group. J Cardiovasc Pharmacol 1990;15(Suppl. 4):S60-S64.
  23. Агеев Ф.Т., Деев А.Д. Применение фелодипина в амбулаторной практике: оценка клинической эффективности и приверженности к лечению у больных с артериальной гипертензией // Кардиология. 2009. Т. 49. № 1. С. 30-33.
  24. Podjarny E, Korzets Z, Bernheim J. Efficacy of low felodipine dose monotherapy in mild-to-moderate hypertension: a comparison between office and ambulatory blood pressure monitoring. J Hum Hypertens 1996;10(Suppl. 3):S153-S156.
  25. Ganz MB, Saska BA. Safety and efficacy of therapeutically equivalent doses of sustained-release formulations of isradipine and felodipine. Congest Heart Fail 2003;Suppl. 2:1-4.
  26. Lefebvre J, Poirier L, Archambault F, et al. Comparative effects of felodipine ER, amlodipine and nifedipine GITS on 24 h blood pressure control and trough to peak ratios in mild to moderate ambulatory hypertension: a forced titration study. Can J Cardiol 1998;14(5):682-88.
  27. Nussinovitch N, Carroll J, Shamiss A, et al. Felodipine in the treatment of severe refractory hypertension. J Hum Hypertens 1996;10(Suppl. 3):S165-67.
  28. Parra D, Beckey NP, Korman L. Retrospective evaluation of the conversion of amlodipine to alternative calcium channel blockers. Pharmacotherapy 2000;20(9):1072-78.
  29. Leenen FH, Coletta E. Pharmacokinetic and antihypertensive profile of amlodipine and felodipine-ER in younger versus older patients with hypertension. J Cardiovasc Pharmacol 2010;56(6):669-75.
  30. Lehrl S, Grassel E, Eicke C. Effectiveness of felodipine in hypertensive patients with mild cerebral cognition disorders in a randomized double-blind study. Dtsch Med Wochenschr 2000;125(45):1350-55.
  31. Dougall HT, McLay J. A comparative review of the adverse effects of calcium antagonists. Drug Saf 1996;15(2): 91-106.
  32. Schaefer RM, Aldons PM, Burgess ED, et al. Improved tolerability of felodipine compared with amlodipine in elderly hypertensives: a randomised, double-blind study in 535 patients, focusing on vasodilatory adverse events. The International Study Group. Int J Clin Pract 1998;52(6):381-86.
  33. Bicchi M, Vedovini G, Cappelli R, et al. Effect of felodipine on arterial blood flow and venous function at rest in patients with mild essential hypertension. Angiology 1998;49(5):373-80.
  34. Zanchetti A, Bold G, Hennig M, et al. Calcium antagonist lacidipin slows down progression of asymptomatic carotid atherosclerosis. Principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 2002;106:2422-27.
  35. Nissen SE, Tuzcu EM, Libby P, et al, CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004;292(18):2217-25.
  36. Ruilope LM, Salvetti A, Jamerson K, et al. Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J Am Soc Nephrol 2001;12(2):218-25.
  37. Schmitz A. Acute renal effects of oral felodipine in normal man. Eur J Clin Pharmacol 1987;32(1):17-22.
  38. Lernfelt B, Landahl S, Johansson P, et al. Haemodynamic and renal effects of felodipine in young and elderly subjects. Eur J Clin Pharmacol 1998;54(8):595-601.
  39. Hasselgren B, Edgar B, Johnsson G, Ronn O. The acute haemodynamic and renal effects of oral felodipine and ramipril in healthy subjects. Eur J Clin Pharmacol 1993;45(4):327-32.
  40. Huysmans FT, van Hamersvelt HW, Sluiter HE, et al. Acute renal effects of felodipine in hypertensive patients with kidney disease. Kidney Int Suppl 1992;36:S106-09.
  41. Herlitz H, Harris K, Risler T, et al. The effects of an ACE inhibitor and a calcium antagonist on the progression of renal disease: the Nephros Study. Nephrol Dial Transplant 2001;16:2158-65.
  42. Bratel T, Hedenstierna G, Nyquist O, Ripe E. The use of a vasodilator, felodipine, as an adjuvant to long-term oxygen treatment in COLD patients. Eur Respir J 1990;3(1):46-54.
  43. Sajkov D, McEvoy RD, Cowie RJ, et al. Felodipine improves pulmonary hemodynamics in chronic obstructive pulmonary disease. Chest 1993;103(5):1354-61.
  44. Sajkov D, Wang T, Frith PA, et al. A comparison of two long-acting vasoselective calcium antagonists in pulmonary hypertension secondary to COPD. Chest 1997;111(6):1622-30
  45. Чазова И.Е., Литвин А.Ю. Артериальная гипертония и синдром обструктивного апноэ во время сна. В кн.: Чазов Е.И., Чазова И.Е. Руководство по артериальной гипертонии. М., Media Medica, 2005. С. 182-200.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>